Phys Clinical Cases · dermatological
Pyoderma Gangrenosum AND Neutrophilic Dermatoses — DCE Clinical Case
DCE long-case and short-case station for Pyoderma Gangrenosum AND Neutrophilic Dermatoses.
On this page & tools
Target exams
Pyoderma Gangrenosum AND Neutrophilic Dermatoses — Clinical Case
DCE Long Case
Patient brief
Patient: A middle-aged or older adult with multimorbidity and a presentation centred on Pyoderma Gangrenosum AND Neutrophilic Dermatoses. [1]
Presenting complaint: Subacute or acute symptoms referable to Pyoderma Gangrenosum AND Neutrophilic Dermatoses, with enough detail to force prioritisation. [1] [2]
Past history: Common cardiometabolic and organ comorbidities that interact with the plan. [2]
Medications: A polypharmacy list that includes at least one interaction or dosing issue. [2]
Examination: Key positives and critical negatives for dangerous differentials. [1]
Investigations: A small set of results that change management. [1] [2]
Tasks
- Present a prioritised problem list. [1]
- Defend investigations and immediate therapy. [1] [2]
- Provide safety-net and follow-up advice. [2]
Model discussion points
- Working diagnosis and acuity. [1]
- Differentials and discriminators. [2]
- Treatment sequence and monitoring. [1] [2] [3]
- Multimorbidity and communication. [2]
Short case
Focused examination or counselling station linked to Pyoderma Gangrenosum AND Neutrophilic Dermatoses, with one interpretation task and one shared-decision point. [1] [2]
References
- [1]Balan K, Elston DM IL-1-targeted therapy in dermatologic conditions J Am Acad Dermatol, 2026.PMID 42264383
- [2]Kerniss H, Olbrich H, Curman P, Ständer S, et al. Pyoderma gangrenosum is associated with excess incident major atherothrombotic events Atherosclerosis, 2026.PMID 42263577
- [3]Rahman S, Akuffo-Addo E, Geng R, Bestavros S, et al. Genital Pyoderma Gangrenosum: A Systematic Review of Reported Cases and Treatment Outcomes J Cutan Med Surg, 2026.PMID 42109214
- [4]Haddadin OM, Jacobson ME, Becker SL, Chen D, et al. Minimum dataset for treatment effectiveness in pyoderma gangrenosum for an international registry: an international multidisciplinary eDelphi consensus Br J Dermatol, 2026.PMID 41784109
- [5]Yamamoto T, Yamasaki K, Yamanaka K, Komine M, et al. Clinical guidance of pyoderma gangrenosum 2022 J Dermatol, 2023.PMID 37311717
- [6]Maverakis E, Ma C, Shinkai K, Fiorentino D, et al. Diagnostic Criteria of Ulcerative Pyoderma Gangrenosum: A Delphi Consensus of International Experts JAMA Dermatol, 2018.PMID 29450466
- [7]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
- [8]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922